The paper that started the extracellular thymosin beta-4 literature, and what it measured

Published 26 October 2026 · REVIVE LAB UAE Research Desk · 5 min read
Malinda and colleagues, in the Journal of Investigative Dermatology in 1999, made full-thickness wounds on the backs of rats and applied full-length thymosin beta-4 topically or by injection, comparing closure with vehicle-treated wounds. Treated wounds closed faster, with more collagen and more new blood vessels, and the peptide increased keratinocyte migration in culture. It was the first demonstration of an extracellular wound-healing activity for a protein until then known as an intracellular actin-binding factor, and it began the literature that led to the RegeneRx programmes.

What was done

Standardised dermal punch wounds in rats, treated with the 43-residue synthetic peptide or vehicle, measured for area over days and examined histologically. In parallel, cultured human keratinocytes were tested for migration in a scratch assay. Both showed effects of the peptide. The study was small and the endpoints were those standard for wound models at the time.

Philp and colleagues extended the work to diabetic and aged mice in 2003 with similar findings.

What it established

That thymosin beta-4 added from outside the cell does something, and that the something includes cell migration and angiogenesis in a wound. Later work from the same groups proposed the actin-binding motif as the active region, which is the origin of the fragment peptides. The eye, cardiac and other programmes followed from this paper.

It is the foundation of the extracellular literature and is cited by nearly everything after it.

The limits

Rodents, skin wounds, the full-length protein, from the laboratories that had discovered the molecule. Human skin-wound trials later gave modest results. None of it was done with a 17-residue fragment, and the transfer from the protein to the fragment is an inference the fragment literature makes rather than demonstrates.

The BPC-157 + TB500 blend is supplied by REVIVE LAB UAE for laboratory research use only, with identity by mass spectrometry and purity by HPLC for each component of the batch. It is not for human or veterinary use, and no dosing, administration or protocol guidance is provided.

What it costs

FormatStrengthPriceAvailability
BPC-157 + TB500 Pack5 mg + 5 mgAED 510In stock

Delivery is AED 40 flat and free on orders over AED 700. Payment is cash on delivery anywhere in the UAE, or USDT (TRC20) in advance, which takes 5% off the order total.

Frequently asked

What was done?

Standardised dermal punch wounds in rats, treated with the 43-residue synthetic peptide or vehicle, measured for area over days and examined histologically. In parallel, cultured human keratinocytes were tested for migration in a scratch assay. Both showed effects of the peptide. The study was small and the endpoints were those standard for wound models at the time.

Does REVIVE LAB UAE provide dosing guidance?

No. REVIVE LAB UAE supplies research materials and provides no dosing, administration or protocol guidance of any kind. Every product is sold for laboratory research use only and is not for human or veterinary consumption.

How fast is delivery in the UAE?

Stock is held in Dubai. An order confirmed before 4 PM Dubai time is dispatched the same working day, reaching Dubai and Abu Dhabi the same day and the remaining emirates within 24 hours. Delivery is AED 40 flat and free over AED 700.

BPC-157 + TB500 Pack — in stock, dispatched from Dubai
HPLC-verified, lot certificate on every carton, 24-hour delivery nationwide. Browse the catalogue → All peptides UAE

Related reading

Supplied for laboratory research use only. Not for human or veterinary consumption. REVIVE LAB UAE provides no dosing, administration or protocol guidance.